Track market-moving stories before they get noisy

Key Takeaways iRhythm will acquire VitalConnect for about $287.5 million, with closing expected by the end of 2026.VitalConnect adds MCT, multi-vitals monitoring and up to 30-day patient monitoring to iRhythm's portfolio.The deal is expected to boost iRhythm's revenue growth rate starting in 2027 and broaden its care reach.
iRhythm Holdings,Inc. (IRTC - Free Report) recently announced that it will acquire Vital Connect, Inc., a leader in wearable biosensor technology and ambulatory cardiac monitoring. The transaction is expected to expand iRhythm’s addressable market and accelerate its evolution from ambulatory cardiac monitoring into a broader cardiac monitoring and intelligence platform spanning ambulatory, inpatient and hospital-to-home care.

Per management, the acquisition marks an important milestone in iRhythm’s transition from ambulatory cardiac monitoring to a broader cardiac monitoring and intelligence platform. The addition of VitalConnect’s mobile cardiac telemetry (MCT), multi-vitals and hospital monitoring capabilities complements the Zio platform, expands the company’s patient and customer reach, and creates opportunities to accelerate growth, strengthen customer relationships and serve patients across a wider continuum of care.

Likely Trend of IRTC Stock Following the NewsShares of IRTC have lost 4% since the announcement on Aug. 6. Year to date, shares of the company have declined 30.6% against the industry’s 4.4% growth and the S&P 500’s 13.6% gain.

In the long run, the acquisition of VitalConnect could strengthen iRhythm’s growth prospects by broadening its cardiac monitoring portfolio and expanding its reach across different care settings. The combination of VitalConnect’s monitoring technologies with iRhythm’s established Zio platform and commercial infrastructure could create new revenue opportunities, strengthen relationships with healthcare providers and support wider adoption. The expanded portfolio also positions iRhythm to capture demand across ambulatory, inpatient and remote care markets, supporting its transition toward a more comprehensive cardiac monitoring platform.

IRTC currently has a market capitalization of $4.13 billion.

Image Source: Zacks Investment Research

More on the NewsThe acquisition broadens iRhythm’s cardiac monitoring capabilities by adding VitalConnect’s FDA-cleared platform, which supports multiple monitoring modalities, including MCT, as well as multi-vitals monitoring. VitalConnect offers capabilities including up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in.

Together with Zio AT and iRhythm’s planned next-generation MCT offering, the combined portfolio is expected to provide clinicians with greater flexibility across different workflows and care settings. VitalConnect’s biosensor platform can monitor up to 11 physiological parameters, extending iRhythm’s reach into inpatient monitoring, remote patient monitoring and hospital-to-home care.

The transaction also combines complementary technology and expertise. VitalConnect contributes wearable biosensors, AI-enabled algorithms and cloud-based workflows, while iRhythm brings cardiac diagnostic expertise, clinical operations, proprietary algorithms and a scaled commercial platform. The integration could support faster product innovation and enable comprehensive solutions for health systems.

Financial Outlook of AcquisitioniRhythm will acquire VitalConnect for approximately $287.5 million, comprising $237.5 million in cash and approximately $50 million in iRhythm common stock. The company will provide up to $30 million in interim working capital financing to support VitalConnect’s operations before closing. The acquisition is anticipated to close by the end of 2026 and expected to be accretive to iRhythm’s revenue growth rate beginning in 2027.

Industry Prospects Favoring the MarketGoing by the data provided by Mordor Intelligence, the cardiac monitoring market is predicted to be valued at $29.1 billion in 2026 and is expected to witness a CAGR of 5.04% through 2035.

Factors like the rising prevalence of cardiovascular diseases, growing geriatric population, technological advances in wireless & wearable devices, expansion of AI-enabled predictive analytics, reimbursement shift to ambulatory continuous monitoring, as well as increasing awareness and screening programs for heart health, are boosting the market’s growth.

Other NewsiRhythm recently delivered strong second-quarter 2026 results with solid earnings and revenue growth. The quarter reflected broad-based commercial momentum across cardiology, primary care, innovative channels and international markets. Innovative channels were the fastest-growing area, supported by value-based care, primary care and population health partnerships.

The company secured FDA clearance for its third-generation algorithm, expected to reduce technician review time by up to 50% and generate approximately $100 million in cumulative savings over five years. iRhythm is also advancing predictive arrhythmia solutions and expanding its Zio platform.

IRTC’s Zacks Rank & Key PicksIRTC currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .

Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Digital healthcare company iRhythm Holdings, Inc. (NASDAQ:IRTC) on Thursday agreed to acquire Vital Connect, Inc., a privately held developer of wearable biosensor technology.

iRhythm Agrees To Acquire VitalConnect for $287.5 MillionThe transaction, valued at approximately $287.5 million, aims to significantly broaden iRhythm’s footprint in ambulatory cardiac monitoring and advanced multi-vitals tracking.

The total purchase price consists of roughly $237.5 million in cash, sourced directly from existing funds on iRhythm’s balance sheet, alongside about $50 million in shares.

To support VitalConnect through the transition, iRhythm will also supply interim working capital financing.

The initial funding starts at $10 million, with additional increments available up to a maximum aggregate of $30 million.

Read Next

Acquisition Broadens Cardiac Monitoring and Multi-Vitals CapabilitiesStrategically, the acquisition integrates VitalConnect’s FDA-cleared technology into iRhythm’s portfolio. This platform features a wide range of cardiac monitoring modalities and multi-vitals tracking capabilities designed for both remote care and hospital settings.

The management expects the buyout to strengthen the company’s long-term growth profile. The integration is projected to become accretive to iRhythm’s overall revenue growth rate beginning in 2027.

The efficiency will help finance future growth investments while maintaining the company’s previously stated adjusted EBITDA margin target of 15% in 2027.

iRhythm reported second quarter adjusted earnings of 58 cents. Sales jumped 20.1% year over year to $224.172 million, beating the consensus of $219.324 million.

The company’s quarterly performance demonstrated robust volume-led revenue growth and expanded margins, with continued momentum across cardiology, primary care, innovative channels, and international markets.

Gross profit was $163.2 million, up 22.8% year over year, while gross margin was 72.8%, a 160-basis point improvement.

The increase in gross profit was primarily due to increased volume of Zio services. The increase in gross margin was primarily driven by continued operational efficiencies, product mix, and scale benefits from higher volumes.

iRhythm Raises Fiscal 2026 Sales GuidanceiRhythm raised its fiscal 2026 sales guidance from $875 million-$885 million to $880 million-$890 million versus the consensus of $881.129 million.

William Blair on Friday wrote, “We expect the company will integrate VitalPatch into the existing Zio Suite software and the company will look to expand using the access to new vitals and other VitalConnect IP.”

“In sum, we think this was a good decision from management as this deal will allow it to further accelerate its top line alongside an eventual MCT launch and bolster its margin profile as the new product ramps up,” analyst Brandon Vazquez wrote.

IRTC Price Action: iRhythm Holdings shares were up 3.68% at $132.84 at the time of publication on Friday, according to Benzinga Pro data.

Read Next

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Top 3 Robotics and Automation Stocks for the Next AI BoomiRhythm Technologies NASDAQ: IRTC reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets.

Get iRhythm Technologies alerts:

Revenue for the quarter ended at $224.2 million, marking iRhythm’s seventh consecutive quarter of growth above 20%, President and Chief Executive Officer Quentin Blackford said. Growth was supported by demand for the company’s Zio ambulatory cardiac-monitoring services across cardiology, primary care, innovative channels and international markets.

4 Stocks With Huge Cash Holdings at Silicon Valley Bank“Volume remained the primary driver of growth,” Chief Financial Officer Dan Wilson said, adding that modest pricing gains and collections execution also supported the quarter. New accounts contributed about 45% of year-over-year volume growth, while the company said several large accounts added in early 2025 have transitioned into its same-store growth category.

Profitability Improves as Revenue Grows Second-quarter gross margin increased 160 basis points year over year to 72.8%, driven by manufacturing automation, workflow improvements, product mix and scale benefits, Wilson said. Adjusted operating expenses were essentially flat at $145 million, compared with $145.2 million in the prior-year period.

The company reported a GAAP net loss of $0.4 million, or $0.01 per diluted share, compared with a GAAP net loss of $14.2 million, or $0.44 per diluted share, a year earlier. Adjusted net income was $19.3 million, or $0.58 per diluted share, compared with an adjusted net loss of $10.2 million, or $0.32 per diluted share, in the second quarter of 2025.

Adjusted EBITDA reached $43.3 million, or 19.3% of revenue, improving by more than 1,000 basis points from the prior-year period. Free cash flow was positive $37.5 million, which Wilson described as a company record. iRhythm ended the quarter with $591.3 million in cash equivalents and marketable securities.

Second-quarter revenue: $224.2 million, up 20.1% year over year. Gross margin: 72.8%, up 160 basis points year over year. Adjusted EBITDA: $43.3 million, or 19.3% of revenue. Free cash flow: $37.5 million. Cash equivalents and marketable securities: $591.3 million. VitalConnect Deal Expands Monitoring Portfolio Blackford said VitalConnect would add a platform spanning mobile cardiac telemetry, or MCT, event monitoring, long-term continuous monitoring and short-term Holter monitoring. Its technology is also FDA-cleared for continuous patient monitoring in hospitals.

VitalConnect’s biosensor can measure up to 11 physiological parameters, including ECG, heart rate, respiratory rate and body temperature. The company said the technology could support future opportunities in inpatient monitoring, hospital-to-home programs and remote patient monitoring.

iRhythm expects VitalConnect to contribute positively to revenue growth beginning in 2027. Wilson said VitalConnect is currently operating at an approximately $65 million annual revenue run rate based on iRhythm’s revenue-recognition approach. The company expects the combined business to maintain gross margin above 70% and said it remains confident in reaching its prior target of a 15% adjusted EBITDA margin in 2027.

The transaction is expected to close by the end of 2026, subject to review. Blackford characterized it as pro-competitive, noting that the MCT market includes competitors such as BioTel and Preventice. He said iRhythm expects to prioritize integration of VitalConnect’s VitalPatch product into its national commercial organization in early 2027.

Management said it intends to maintain a multi-product MCT strategy. Zio AT, Zio MCT and VitalPatch address different physician, patient and workflow preferences, according to Blackford. While the company remains focused on obtaining FDA clearance for Zio MCT during the first half of 2027, VitalPatch will be the near-term priority for commercial integration if the acquisition closes as anticipated.

Wilson said the deal includes $50 million in equity, calculated using a 30-day volume-weighted average price, equating to a little more than 420,000 shares and less than 1.5% dilution.

Primary Care, AI and International Initiatives iRhythm continued to target earlier identification of arrhythmias through primary care, value-based care and population-health settings. Blackford said the company estimates that at least 27 million people in the United States are at risk for arrhythmias, with many first entering the healthcare system through primary care.

During the quarter, iRhythm signed two commercial agreements through its partnership with Lucem to combine predictive identification workflows with iRhythm monitoring. It also expanded work with Desert Oasis Healthcare using AI-driven analytics to identify patients who may benefit from cardiac evaluation and monitoring.

The innovative channel was iRhythm’s fastest-growing channel during the quarter. Early pilot programs have demonstrated more than 85% accuracy in identifying patients with clinically relevant arrhythmias before they enter the diagnostic process, Blackford said. The company also began direct-to-patient educational initiatives through the PatientPoint network and said it expects to continue investing in those efforts during the second half of the year.

Approximately 60% of iRhythm’s volume now comes from EHR-integrated accounts, with nearly 80 of its top 100 customers integrated, Blackford said. Internationally, the company cited progress with the U.K.’s National Health Service, relationships with key opinion leaders in the Netherlands, and a higher reimbursement rate in Japan that took effect June 1.

Regulatory Updates and Raised Outlook iRhythm said final local coverage determinations issued by Noridian, CGS and Palmetto clarified modality-specific coverage without adding access restrictions. Wilson also said preliminary CMS physician-fee-schedule proposals indicated reimbursement rate increases in the low-single-digit percentages for long-term continuous monitoring and MCT.

The company received FDA clearance for its third-generation algorithm, which it plans to launch across its platform in the first half of 2027. Blackford said the algorithm is expected to reduce clinical technician review time by as much as 50% and generate approximately $100 million in cumulative cost savings over five years.

iRhythm remains subject to an FDA warning letter. Blackford said the company has updated the agency on completed remediation activities and a self-initiated third-party audit, while awaiting the FDA’s further review.

The company also disclosed that it settled outstanding litigation with Baxter and its subsidiaries, Welch Allyn and Bardy Diagnostics, on July 31 for a $50 million payment. Separately, iRhythm said a June cybersecurity incident involving certain third-party-hosted business applications was contained and did not materially affect products, patient care, operations or financial results.

For 2026, iRhythm raised revenue guidance to $880 million to $890 million, representing growth of 18% to 19%. Third-quarter revenue is expected to range from $221 million to $223 million. The company increased its full-year adjusted EBITDA margin outlook to 13% to 14%, while projecting a third-quarter adjusted EBITDA margin of 12% to 13%.

About iRhythm Technologies (NASDAQ:IRTC)iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company's flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm's digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in iRhythm Technologies Right Now?Before you consider iRhythm Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRhythm Technologies wasn't on the list.

While iRhythm Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report